Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pivhydrazine SCHEMBL149084 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2RIPK1POLBLMNACYP1A2 | |
| Pivhydrazine SCHEMBL9551290 | 0.88 | SMN1; SMN2 (0.55) | SMN1; SMN2RIPK1POLBLMNACYP1A2 | |
| SCHEMBL24847549 | 0.73 | CYP1A2 (0.54) | SMN1; SMN2LMNACYP1A2PTGS2CYP3A4 | |
| SCHEMBL1653407 | 0.73 | CYP1A2 (0.54) | SMN1; SMN2LMNACYP1A2PTGS2CYP3A4 | |
| SCHEMBL1516186 | 0.72 | RIPK1 (0.71) | SMN1; SMN2RIPK1POLBLMNACYP1A2 | |
| SCHEMBL9551367 | 0.71 | RECQL (0.48) | SMN1; SMN2RIPK1POLBLMNACYP1A2 | |
| SCHEMBL294698 | 0.71 | IDO1 (0.48) | SMN1; SMN2LMNACYP1A2PTGS2CYP3A4 | |
| SCHEMBL9551354 | 0.70 | ANPEP (0.49) | SMN1; SMN2MMP8 | |
| SCHEMBL8843180 | 0.70 | LMNA (0.59) | SMN1; SMN2RIPK1POLBLMNACYP1A2 | |
| SCHEMBL4418820 | 0.70 | LMNA (0.51) | SMN1; SMN2LMNACYP1A2PTGS2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2506717-B1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PERKINELMER INC (US) | 2015-03-25 | — | — | EP | claimed |
| US-20130131127-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. | 2013-05-23 | — | — | US | claimed |
| EP-2506717-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PerkinElmer, Inc. (US) | 2012-10-10 | — | — | EP | claimed |
| WO-2011069051-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. (US) | 2011-06-09 | — | — | WO | claimed |
| US-20170056379-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20150366846-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES INC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9119843-B2 | Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions | CALIPER LIFE SCIENCES, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2506717-B1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PERKINELMER INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130131127-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. | 2013-05-23 | — | — | US | disclosed |
| EP-2506717-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | PerkinElmer, Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069051-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | CALIPER LIFE SCIENCES, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056379-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | SLC6A3, SLC6A2, DBH | SMN1; SMN2 405/4885RIPK1 2167/4885POLB 3904/4885 |
| US-20150366846-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | SLC6A3, SLC6A2, DBH | SMN1; SMN2 405/4885RIPK1 2167/4885POLB 3904/4885 |
| US-20130131127-A1 | METHOD OF USING DOPAMINE REUPTAKE INHIBITORS AND THEIR ANALOGS FOR TREATING DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES-ASSOCIATED PATHOLOGIC CONDITIONS | SLC6A3, SLC6A2, DBH | SMN1; SMN2 405/4885RIPK1 2167/4885POLB 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.